PUBLISHER: Grand View Research | PRODUCT CODE: 1446550
PUBLISHER: Grand View Research | PRODUCT CODE: 1446550
The global demineralized bone matrix market size is expected to reach USD 1.97 billion by 2030, registering a CAGR of 5.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is anticipated to witness significant growth owing to the increasing investment of the government in the advancement of research related to orthopedic diseases. For instance, in 2021, the Orthopedic Surgery program at the Perelman School of Medicine, University of Pennsylvania, secured over USD 10 million in NIH grants, further demonstrating the significance of this area of research.
Increasing prevalence of spinal cord injuries across the globe is anticipated to boost market growth. According to the NIH report of 2022, an estimated 250,000 to 500,000 individuals globally suffer from spinal cord injuries every year. Most of these cases are preventable and are caused by factors such as trauma and motor vehicle accidents. In the United States alone, about 17,000 new spinal cord injury cases are reported annually, with an estimated 282,000 individuals living with SCI. Males are more likely to experience SCI due to sports injuries, and the age group with the highest risk is between 16 to 30 years old.
The increasing prevalence of orthopedic disorders across the globe is expected to boost market growth. For instance, the Lancet Rheumatology estimates published in 2023 indicate that by 2050, almost one billion individuals will be diagnosed with osteoarthritis, the most prevalent type of arthritis. Similarly, as per the GVR internal data base, in 2023, the number of people affected with osteoarthritis are 11.4 million in 2023. Such rising cases of orthopedic disorders will boost the demand for demineralized bone matrix (DBM).
The major players operating in the market are adopting strategies such as collaborations, supply agreements, and partnerships with a major focus on enhancing product formation and reach. For instance, in March 2022, Bone Biologics Corporation, a developer of orthobiologic products, signed a supply agreement with MTF Biologics. The agreement is for the supply of demineralized bone matrix (DBM). Bone Biologics is developing a bone graft substitute product that consists of rhNELL-1 and a carrier, which will be supplied by MTF Biologics. The product aims to initiate and improve bone formation.
Additionally, a growing patient base with an increasing aging population will supplement market growth. For instance, according to an NIH report, osteoarthritis (OA) is a joint disease that affects more than 80% of individuals over the age of 55. In addition, as per the NHIS report from 2019 to 2021 in the U.S., 26% of adults between the ages of 45 and 64 reported being diagnosed with arthritis by a doctor. The report also found that almost half (47.3%) of adults aged 65 or older reported being diagnosed with arthritis by a doctor.